DMT310-009 Topical in the Treatment of Acne Vulgaris

• Status: Recruiting
• Trial end date: 2025-03-30
• Target enrollment: 0
• Participant gender: All

Summary

The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dermata Therapeutics

Criteria

Inclusion Criteria:

• Patient sex at birth, male or non-pregnant female at least 9 years of age

• Clinical diagnosis of moderate to severe acne vulgaris as determined by:

Investigator's Global Assessment (IGA) at Randomization; Patient has at least 20 inflammatory lesions and at least 20 noninflammatory lesions on the face

• Patient is willing to apply the Investigational Product as directed

• Patient is willing and able to comply with the protocol

Exclusion Criteria:

• Patient is pregnant or planning to become pregnant

• Patient is taking a topical therapy on the face which may affect the patient's acne